Human CD19+ B cells isolated from peripheral blood using positive immunomagnetic selection, cryopreserved, ≥10 million cells
Human Peripheral Blood CD14+ Monocytes, Cryopreserved, Negative Selection, 10 million
Cryopreserved ampule of Human Peripheral Blood CD14+ Monocytes, negative selection, containing ≥10 million cells
Cryopreserved ampule of negatively selected Human Peripheral Blood CD14+ Monocytes, containing ≥ 50 million cells
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 10 Million
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing 10 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 5 million cells
Human CD19+ B cells isolated from peripheral blood using negative immunomagnetic selection, cryopreserved, ≥10 million cells
Do you need a modified version of this cell product, such as different vialing sizes, matched immune cell isolations or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
-
Normal Peripheral Blood CD4+ T LymphocytesLonza Application Notes
-
Cryopreservation of Peripheral Blood Mononuclear CellsDoes Not Alter Immune Cell Phenotype
-
Validation of Th17 Cell Differentiation from Peripheral BloodLonza White Paper
-
Predicting Antibody Dependent Cell-Mediated Cytotoxicity (ADCC)Genotypic and Phenotypic Screening of Human Peripheral Blood Mononuclear Cells
-
TechSheet - Normal Human Dendritic Cell SystemTechnical Information Sheet for Poietics™ Normal Human Dendritic Cell System
-
siRNA Transfection Protocol for Blood LymphocytesInstructions of use for transfection of human peripheral blood lympohocytes with siRNA using the Nucleofector™ Technology
-
Two Distinct Activation Methods Yield Clinical-Scale Expansion of Peripheral Blood Derived γδ T CellsIn this study, we demonstrate that billions of γδ T cells can be generated from peripheral blood mononuclear cells (PBMCs) with two distinct activation methods, using TheraPEAK® T-VIVO® Medium.
-
Transfection Protocol for Human T Cells (Stim.) - 96-well Shuttle™ DeviceInstructions of use for transfection of stimulated peripheral blood human T cells with the P3 Primary Cell 96-well Nucleofector™ Kit
-
Transfection Protocol for Human T Cells (Unstim.) - 96-well Shuttle™ DeviceInstructions of use for transfection of unstimulated peripheral blood human T cells with the P3 Primary Cell 96-well Nucleofector™ Kit
-
Transfection Protocol for Human T Cells (Stim.) - 4D-Nucleofector™ DeviceInstructions of use for transfection of stimulated peripheral blood human T cells with the P3 Primary Cell 4D-Nucleofector™ X Kit